Intervention in gastro-enteropancreatic neuroendocrine tumours

Best Pract Res Clin Gastroenterol. 2012 Dec;26(6):855-65. doi: 10.1016/j.bpg.2013.01.008.

Abstract

Neuroendocrine tumours require dedicated interventions to control their capacity to secrete hormones but also, antitumour growth strategies. Recommendations for early interventions in NET include the management of hormone-related symptoms and poorly differentiated neuroendocrine carcinomas. In contrast, prognostic heterogeneity is a key feature of well differentiated NET that complexified the antitumour strategy whatever the stage in this subgroup of tumour. In this review, timely therapeutic interventions to control hormone-related symptoms and tumour growth in GEP NET patients are discussed. The necessity of controlling hormone-related symptoms as the first step of any strategy affects also the tumour growth control strategy. In the absence of cure at the metastatic stage, progresses are expected in the recognition of well differentiated NET subgroups that display either excellent or poor prognosis.

Publication types

  • Review

MeSH terms

  • Antineoplastic Agents, Hormonal / therapeutic use*
  • Bronchial Neoplasms / complications
  • Bronchial Neoplasms / metabolism
  • Bronchial Neoplasms / mortality
  • Bronchial Neoplasms / pathology
  • Bronchial Neoplasms / therapy*
  • Carcinoid Tumor / complications
  • Carcinoid Tumor / metabolism
  • Carcinoid Tumor / mortality
  • Carcinoid Tumor / pathology
  • Carcinoid Tumor / therapy*
  • Humans
  • Intestinal Neoplasms / complications
  • Intestinal Neoplasms / metabolism
  • Intestinal Neoplasms / mortality
  • Intestinal Neoplasms / pathology
  • Intestinal Neoplasms / therapy*
  • Neuroendocrine Tumors / complications
  • Neuroendocrine Tumors / metabolism
  • Neuroendocrine Tumors / mortality
  • Neuroendocrine Tumors / pathology
  • Neuroendocrine Tumors / therapy*
  • Pancreatic Neoplasms / complications
  • Pancreatic Neoplasms / metabolism
  • Pancreatic Neoplasms / mortality
  • Pancreatic Neoplasms / pathology
  • Pancreatic Neoplasms / therapy*
  • Prognosis
  • Randomized Controlled Trials as Topic
  • Stomach Neoplasms / complications
  • Stomach Neoplasms / metabolism
  • Stomach Neoplasms / mortality
  • Stomach Neoplasms / pathology
  • Stomach Neoplasms / therapy*

Substances

  • Antineoplastic Agents, Hormonal

Supplementary concepts

  • Gastro-enteropancreatic neuroendocrine tumor